Clinical trial
Evaluation of CYP2C9 Activity
NCT00162461 · Hadassah Medical Organization, Other · Unknown status
Key facts
| NCT number | NCT00162461 |
|---|---|
| Title | Evaluation of CYP2C9 Activity |
| Official title | The Use of Phenytoin Metabolic Ratio as a Putative Marker of CYP2C9 Activity In-vivo |
| Lead sponsor | Hadassah Medical Organization, Other |
| Collaborators | United States - Israel Binational Science Foundation |
| Status | Unknown status |
| Study type | Interventional |
| Conditions | Healthy |
| Intervention type | Drug |
| Interventions | Phenytoin single dose (300 mg) |
| Enrollment | 1,200 |
| Start date | Aug 1, 1998 |
| Primary completion | Dec 1, 2020 |
| Completion | Dec 1, 2020 |
| First posted | Sep 13, 2005 |
| Last update posted | Jun 12, 2018 |
| Countries | Israel |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: